Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.
Clavio M, Gatto S, Beltrami G, Cerri R, Carrara P, Pierri I, Canepa L, Miglino M, Balleari E, Masoudi B, Damasio E, Ghio R, Sessarego M, Gobbi M. Clavio M, et al. Among authors: miglino m. Leuk Lymphoma. 2001 Jan;40(3-4):305-13. doi: 10.3109/10428190109057929. Leuk Lymphoma. 2001. PMID: 11426552 Clinical Trial.
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, Galbusera V, Carrara P, Miglino M, Varaldo R, Ballerini F, Venturino C, Cerri R, Risso M, Balleari E, Carella AM, Sessarego M, Ghio R, Bacigalupo A, Gobbi M. Clavio M, et al. Among authors: miglino m. J Exp Clin Cancer Res. 2002 Dec;21(4):481-7. J Exp Clin Cancer Res. 2002. PMID: 12636093
Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
Balleari E, Clavio M, Arboscello E, Bellodi A, Bruzzone A, Del Corso L, Lucchetti MV, Miglino M, Passalia C, Pierri I, Ponassi I, Oneto C, Racchi O, Scudeletti M, Vignolo L, Zoppoli G, Gobbi M, Ghio R. Balleari E, et al. Among authors: miglino m. Leuk Res. 2011 Nov;35(11):1472-6. doi: 10.1016/j.leukres.2011.05.025. Epub 2011 Jul 26. Leuk Res. 2011. PMID: 21794914
Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis.
Aquino S, Clavio M, Rossi E, Vignolo L, Miglino M, Spriano M, Canepa L, Catania G, Pierri I, Bergamaschi M, Gonella R, Marani C, Racchi O, Cavaliere M, Goretti R, Carbone F, Bruzzone A, Tassara R, Carella AM, Ghio R, Gobbi M. Aquino S, et al. Among authors: miglino m. Oncol Lett. 2011 Mar;2(2):289-295. doi: 10.3892/ol.2011.255. Epub 2011 Jan 21. Oncol Lett. 2011. PMID: 22866079 Free PMC article.
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
Clavio M, Cruciani F, Minetto P, Guolo F, Ballerini F, Marani C, De Astis E, Aquino S, Bergamaschi M, Mitscheunig L, Grasso R, Colombo N, Ghiggi C, Lovera D, Pastori G, Avenoso D, Miglino M, Gobbi M. Clavio M, et al. Among authors: miglino m. Ann Hematol. 2013 Oct;92(10):1309-18. doi: 10.1007/s00277-013-1780-7. Epub 2013 May 18. Ann Hematol. 2013. PMID: 23686116
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.
Balleari E, Salvetti C, Del Corso L, Filiberti R, Bacigalupo A, Bellodi A, Beltrami G, Bergamaschi M, Berisso G, Calzamiglia T, Carella AM, Cavalleri M, Da Col A, Favorini S, Forni GL, Goretti R, Miglino M, Mitscheuning L, Molinari E, Racchi O, Scudeletti M, Tassara R, Gobbi M, Lemoli R, Clavio M. Balleari E, et al. Among authors: miglino m. Leuk Res. 2015 Aug;39(8):846-52. doi: 10.1016/j.leukres.2015.05.007. Epub 2015 Jun 22. Leuk Res. 2015. PMID: 26145790
386 results